Soliris Injection, Solution, Concentrate
Product Images NDC 25682-001

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Soliris (NDC 25682-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alexion Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (30 mL Vial Carton)

A Kaplan-Meier survival curve showing the proportion relapse-free over time in weeks during a clinical study period. The graph compares two groups: one receiving Eculizumab, with a consistently high relapse-free proportion around 1.0, and the other receiving placebo, which shows a decreasing relapse-free proportion over time. The inset includes statistical values such as relapse-free proportions at 48 weeks and a log rank p-value indicating significant difference between groups.*

FDA Label Image

Soliris 02

Packaging label for Soliris (eculizumab) injection, solution, concentrate, 300 mg/30 mL (10 mg/mL) single-dose vial by Alexion Pharmaceuticals Inc. The label includes dosing information, storage instructions (refrigerate 2-8°C, protect from light, do not freeze or shake), and notes that the solution must be diluted prior to intravenous use. Contains no preservatives and lists inactive ingredients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.